Bronchiectasis

SpliSense Announces FDA Clearance of Investigational New Drug Application for Phase 2 Initiation of SPL84 for the Treatment of Cystic Fibrosis

Retrieved on: 
Wednesday, April 3, 2024
Mutation, Disease, RNA, Doctor of Philosophy, IND, Life expectancy, Asthma, IPF, Idiopathic pulmonary fibrosis, Investigational New Drug, Bronchiectasis, CFTR, COPD, FDA, Cystic fibrosis, Food, Pharmaceutical industry

JERUSALEM, April 3, 2024 /PRNewswire/ -- SpliSense, a clinical-stage biotechnology company focused on the development of transformative RNA-based therapies for pulmonary diseases including cystic fibrosis (CF), muco-obstructive diseases like COPD, asthma, non-CF bronchiectasis (NCFB) and idiopathic pulmonary fibrosis (IPF), today announced that the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application for the initiation of a Phase 2 study for SPL84 in CF. SPL84 is the Company's lead antisense oligonucleotide (ASO) product for the treatment of people with CF carrying the 3849+10 kilobase (Kb) C->T splicing mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Key Points: 
  • SPL84 is the Company's lead antisense oligonucleotide (ASO) product for the treatment of people with CF carrying the 3849+10 kilobase (Kb) C->T splicing mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
  • The Company has also announced today that it has secured funding from the CF Foundation and other existing investors to support the SPL84 Phase 2 study and additional pulmonary programs.
  • "We are excited to initiate the Phase 2 study for SPL84 in CF with the support of the CF Foundation and other existing investors," said Gili Hart, PhD, Chief Executive Officer of SpliSense. "
  • Our lead product, SPL84, has been shown to fully restore CFTR activity in the CF gold standard pharmacological model.

EQS-News: AATec Medical appoints Professor Dr. Claus Franz Vogelmeier to the Scientific Advisory Board

Retrieved on: 
Wednesday, March 13, 2024
Bronchiectasis, American Journal, Pulmonology, Asthma, AAT, European Respiratory Society, FERS, GOLD, Patient, Chronic obstructive pulmonary disease, Global Initiative, German Respiratory Society, Critical Care Medicine (journal), COPD, Pharmaceutical industry

AATec Medical appoints Professor Dr. Claus Franz Vogelmeier to the Scientific Advisory Board

Key Points: 
  • AATec Medical appoints Professor Dr. Claus Franz Vogelmeier to the Scientific Advisory Board
    The issuer is solely responsible for the content of this announcement.
  • AATec Medical appoints Professor Dr. Claus Franz Vogelmeier to the Scientific Advisory Board
    Leading pulmonology expert contributes profound clinical experience in inflammatory lung diseases such as bronchiectasis, COPD, asthma, and ARDS to AATec Medical.
  • Munich, Germany – 29.02.2024 – AATec Medical GmbH (AATec), a biotech company developing a multi-product platform technology based on recombinant alpha-1 antitrypsin (AAT), today announced the appointment of Prof. Dr. Claus Franz Vogelmeier, Professor of Medicine and Head of the Department of Pulmonary Medicine at Philipps-University in Marburg, Germany to its Scientific Advisory Board.
  • Dr. Rüdiger Jankowsky, co-founder and CEO of AATec, commented: “We are very pleased to welcome Professor Vogelmeier to our Scientific Advisory Board.

Vast Therapeutics Expands Leadership Team with Appointment of Dr. Paul Bruinenberg as Chief Medical Officer

Retrieved on: 
Thursday, March 7, 2024
Rochester University, Bronchiectasis, Roche, Cystic fibrosis, MD, NIH, Medical director, Nephrotoxicity, Astellas Pharma, MBA, TB, ARUP Laboratories, University of Utah, University, Therapy, Pathology, TB Alliance, Associate, Patient, Duke University, Diagnosis, Tuberculosis, Pseudomonas aeruginosa, NTM, Publication, IND, Pharmaceutical industry

MORRISVILLE, N.C., March 7, 2024 /PRNewswire/ -- Vast Therapeutics today announced the addition of Paul Bruinenberg, MD, MBA as Chief Medical Officer. Dr. Bruinenberg brings over 30 years of experience as a clinical development executive in respiratory medicine and orphan diseases. This appointment and the recent addition of microbiologist and clinical diagnostics expert Chris Polage, MD, as Medical Director, significantly bolster the company's clinical development expertise in pulmonary infectious diseases and medical microbiology. 

Key Points: 
  • MORRISVILLE, N.C., March 7, 2024 /PRNewswire/ -- Vast Therapeutics today announced the addition of Paul Bruinenberg, MD, MBA as Chief Medical Officer.
  • "Paul's development experience will guide Vast Therapeutics as we successfully transition to a clinical-stage organization," said Nate Stasko, Chief Executive Officer at Vast Therapeutics.
  • "It is an amazing opportunity to join a company with an accepted IND for a novel treatment modality that shows promising efficacy against chronic infections caused by Pseudomonas aeruginosa and non-tuberculosis mycobacteria," commented Paul Bruinenberg, Chief Medical Officer at Vast Therapeutics.
  • Most recently, Dr. Bruinenberg served as the Senior Medical Officer of the TB Alliance leading clinical development against mycobacterial infections.

Actress Jane Seymour and Insmed Raise Awareness of "Unseenism" and Empower People to Speak Up When It Comes to Their Health

Retrieved on: 
Wednesday, February 28, 2024
Television, Woman, Bronchiectasis, Education, Mucus, Ageing, Hope, Communication, Prevalence, Health, Bacteria, Human, Patient, Flare, Diagnosis, Respiratory disease, Nursing

"In both my television and film roles and in real life, I've always tried to push back against the typical notions of aging and feeling unseen.

Key Points: 
  • "In both my television and film roles and in real life, I've always tried to push back against the typical notions of aging and feeling unseen.
  • Being older shouldn't mean you are no longer valuable or relevant," said Seymour.
  • The survey of over 2,000 participants, conducted by Insmed, aimed to uncover how "Unseenism" can shape the health decisions of people aged 40+ years.
  • 72% said being knowledgeable about their health makes them feel empowered to speak up with healthcare providers.

Renovion Completes Enrollment of Adult Patients in Phase 2 CLIMB Study in Bronchiectasis

Retrieved on: 
Thursday, January 11, 2024
Biotechnology, Medical Devices, Health, Pharmaceutical, Clinical Trials, Bronchiectasis, Quality of life, Inc., Inflammation, Patient, Infection, Safety, Mucus, Pharmaceutical industry

Renovion Inc., a biopharmaceutical company focused on restoring lung health in patients with bronchiectasis and other lung diseases, announced that adult patient enrollment is complete in the Phase 2 CLIMB study of ARINA-1 in non-CF bronchiectasis patients.

Key Points: 
  • Renovion Inc., a biopharmaceutical company focused on restoring lung health in patients with bronchiectasis and other lung diseases, announced that adult patient enrollment is complete in the Phase 2 CLIMB study of ARINA-1 in non-CF bronchiectasis patients.
  • CLIMB is a US based, randomized, double-blind, placebo-controlled Phase 2 study to evaluate the safety, tolerability and efficacy of ARINA-1 in participants with bronchiectasis.
  • "We are pleased to report that we have completed adult patient enrollment in the CLIMB study for bronchiectasis.
  • This is a great milestone for our company and for people living with bronchiectasis," said Dan Copeland, Chief Executive Officer of Renovion.

Velocity expands to 17 sites in Europe

Retrieved on: 
Wednesday, January 3, 2024
Centra, Quality of life, Family, Pulmonary fibrosis, Research, Acquisition, Asthma, Medical director, MD, Pi, Clinical trial, Heart, CEE, ChromeOS, Patient, Corporate development, Bronchiectasis, Digitalization, KLB

Velocity’s growth is accelerating across Europe, with 17 locations in the U.K., Poland and Germany.

Key Points: 
  • Velocity’s growth is accelerating across Europe, with 17 locations in the U.K., Poland and Germany.
  • The company is now one of the largest site organisations in Europe in addition to it being the largest sites business in the United States.
  • Velocity is building an integrated network of sites that can change the paradigm and we have the size and scale where we can recruit enough patients, either for entire studies or contribute significantly to country targets in Europe.
  • Anne-Marie Kirsten, MD PhD and Henrik Watz, MD PhD both join Velocity as principal investigators (PIs), being leaders in Pulmonary research in Europe.

Chiesi Group signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel, reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis

Retrieved on: 
Monday, November 20, 2023
Bronchiectasis, Respiratory disease, Patient, End-user license agreement, Partnership, DPP1, Pharmaceutical industry, Chiesi Farmaceutici

Chiesi Group and Haisco Pharmaceutical will collaborate closely to develop HSK31858, a novel reversible dipeptidyl peptidase 1 (DPP1) inhibitor for respiratory diseases.

Key Points: 
  • Chiesi Group and Haisco Pharmaceutical will collaborate closely to develop HSK31858, a novel reversible dipeptidyl peptidase 1 (DPP1) inhibitor for respiratory diseases.
  • This agreement expands Chiesi's comprehensive R&D program in bronchiectasis, a respiratory disease with high unmet medical needs, for which no approved treatment is available to date.
  • Haisco Pharmaceutical will receive an upfront payment and future milestone payments, including royalties on product sales.
  • Under the terms of the agreement, Chiesi will make an upfront payment and additional contingent milestone payments to Haisco, including royalties on product sales.

Chiesi Group signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel, reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis

Retrieved on: 
Monday, November 20, 2023
Bronchiectasis, Respiratory disease, Patient, End-user license agreement, Partnership, DPP1, Pharmaceutical industry, Chiesi Farmaceutici

Chiesi Group and Haisco Pharmaceutical will collaborate closely to develop HSK31858, a novel reversible dipeptidyl peptidase 1 (DPP1) inhibitor for respiratory diseases.

Key Points: 
  • Chiesi Group and Haisco Pharmaceutical will collaborate closely to develop HSK31858, a novel reversible dipeptidyl peptidase 1 (DPP1) inhibitor for respiratory diseases.
  • This agreement expands Chiesi's comprehensive R&D program in bronchiectasis, a respiratory disease with high unmet medical needs, for which no approved treatment is available to date.
  • Haisco Pharmaceutical will receive an upfront payment and future milestone payments, including royalties on product sales.
  • Under the terms of the agreement, Chiesi will make an upfront payment and additional contingent milestone payments to Haisco, including royalties on product sales.

3 ways to prepare for bushfire season if you have asthma or another lung condition

Retrieved on: 
Thursday, October 26, 2023
People, Smoke, Well, Ozone, Health, Spasm, Nitrogen dioxide, Wheeze, Asthma, Atmosphere, Death, Bronchiectasis, City, Nasal congestion, Particulates, Oxygen, Travel, HEPA, Sulfur dioxide, Burn, Gas, Chronic obstructive pulmonary disease, Emergency, Firewood, Antibiotics, Kerosene, Airline, Hospital, Pharmaceutical industry, Personal protective equipment, Management

This not only affects people in bushfire regions, but those in cities and towns far away, as smoke travels.

Key Points: 
  • This not only affects people in bushfire regions, but those in cities and towns far away, as smoke travels.
  • But after early heatwaves and bushfires, this year may be different
    What’s so dangerous about bushfire smoke?
  • Bushfire smoke pollutes the air we breathe by increasing the concentration of particulate matter (or PM).
  • If you have asthma, chronic obstructive pulmonary disease, bronchiectasis or another lung condition, or you care for someone who has, here’s what you can do to prepare for the season ahead.

Inogen Completes Acquisition of Physio-Assist

Retrieved on: 
Monday, September 18, 2023
Biotechnology, Medical Devices, Health, Health Technology, Managed Care, CE, Marketing, Sale, Chronic obstructive pulmonary disease, Acquisition, Patient, Bronchiectasis, Cystic fibrosis, FDA, Pharmaceutical industry, EU

Inogen, Inc. (Nasdaq: INGN ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced it has completed the acquisition of Physio-Assist SAS, expanding the company’s innovative respiratory portfolio.

Key Points: 
  • Inogen, Inc. (Nasdaq: INGN ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced it has completed the acquisition of Physio-Assist SAS, expanding the company’s innovative respiratory portfolio.
  • Inogen will leverage its commercial infrastructure and capabilities to continue marketing the device in these geographies while pursuing US regulatory approvals.
  • The acquisition may provide access to a large and growing market opportunity with 400,000 to 490,000 patients suffering from bronchiectasis in the US eventually.
  • As previously communicated, the acquisition is expected to be immaterial to Inogen’s 2023 revenue and immediately accretive to gross margin.